Perlmutter Cancer Center at NYU Langone Health
@Perlmutter_CC
Followers
1K
Following
2K
Media
740
Statuses
2K
We combine visionary thinking and compassionate care with the science of treating cancer. An NCI-designated Comprehensive Cancer Center, part of @NYULangone
New York, NY
Joined January 2022
RT @jane_skok: We’re back! Registration is NOW OPEN for the 6th Annual Meeting on Advances in Nuclear Topology & 3D Chromatin Architecture….
0
6
0
RT @Aiims1742: New birthday, new city, new job, new beginnings! 🥳.Delighted to start in my new role at @nyulangone @Perlmutter_CC. Looking….
0
11
0
RT @VJOncology: 🎥@JaniceM10 of @Perlmutter_CC discusses adding sarilumab to checkpoint inhibitors in unresectable melanoma. Blocking IL-6 m….
0
2
0
RT @docbraunstein: Join me and my colleagues from @Perlmutter_CC on September 30 for a virtual discussion for the patient and caregiver com….
nyulangone.zoom.us
Breakthroughs in science are transforming how we care for patients with Leukemia, Lymphoma, and Myeloma — offering more targeted, effective, and compassionate approaches than ever before. Join...
0
2
0
🫀Join @drmishbloom for a vital discussion on #HeartDisease in adult cancer #Survivorship. Learn about treatment-related cardiac risks, who’s most vulnerable, key warning signs, and prevention & care strategies. All are welcome. RSVP:
0
1
3
RT @OncLive: UGN-102 Redefines Treatment Standards for Low-Grade, Intermediate-Risk NMIBC.@UroWCH @nyulangone #BladderCancer #blcsm.https:/….
onclive.com
William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.
0
3
0
RT @OncBrothers: One page takeaway/summary from our 🗣️ with @JSabari and Beamion-Lung1 study that resulted in #Zongertinib @FDAOncology app….
0
6
0
RT @petersliang: Proud to share the new @C5NYC PSA on colorectal cancer screening in Mandarin Chinese: Hope this i….
0
7
0
RT @theLundLab: We are putting together an exciting program with fresh perspectives and new biology!! Come join us next year in Portugal! @….
0
9
0
RT @BPothuri: Thanks @NaamitGerber! Excited that @Perlmutter_CC is ranked #4 for NRG main member accrual! Keep up great work all- more pati….
0
1
0
RT @OncologyTimes: @Perlmutter_CC has named Augusto Villanueva Rodriguez, MD, PhD, a renowned hepatologist, as the new Academic Director an….
0
1
0
RT @JSabari: FDA approval for lung cancer med Hernexeos @Perlmutter_CC @nyulangone @EGFRResisters @Exon20Group.
fiercepharma.com
With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer Ingelheim is entering the oncology market. | Zongertinib got an accelerated...
0
2
0
Join us at @NYULangoneLI on October 3rd for a live CME program to learn the latest diagnosis & treatment modalities in #BreastCancer care from a panel of nationally recognized experts. RSVP (early bird deals ends 8/30):
0
0
0
RT @nyulangone: NYU Langone Health gastroenterologist @DrLaPook explains a promising trend in early-stage detection ⤵️.
0
5
0
0
2
0
RT @NYULH_GastroHep: Can't wait to hear Dr. Augusto Villanueva Rodriguez present on "The Evolving Landscape of Care in Hepatocellular Carc….
0
4
0
Nearly a year after his passing, we honor Dr. Jeffrey Weber—a visionary in melanoma care and research. His legacy lives on through the lives he touched, the careers he shaped, and the science he advanced. Learn about his impact on @ASCO's #ASCOConnection:
0
1
12
RT @nyugrossman: Dr. Augusto Villanueva is leading a new chapter in liver cancer care at NYU Langone—advancing early detection through liqu….
0
4
0
RT @NYUDocs: Coming up at 2:30pm East, join @DrMarcSiegel as he speaks with incoming Dean & CEO of @nyulangone, Dr. Alec Kimmelman, MD, PhD….
0
4
0